Trial reportSurgical endoscopy2025
Intraoperative botulinum toxin injection in sleeve gastrectomy, a pilot randomized controlled trial.
Trial report in Surgical endoscopy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBotulinum toxin injection of the pylorus (BP) improves gastric transit after esophagectomy (Saeed et al. in Surg Endosc 38(10):6046-52, 2024). At our institution, BP has been used as an adjunct to sleeve gastrectomy (SG) to reduce post-operative nausea and vomiting (PONV). We studied the safety and efficacy of this practice.
methodsA prospective, double-blinded randomized controlled trial of SG was performed with and without intraoperative BP at a large tertiary care medical center over a 3-year period was done. The primary outcome measured was safety of intraoperative BP during SG and followed by efficacy in treating PONV.
resultsWe performed a prospective RCT on 57 SGs performed from 2019 to 2022. There were no differences in operative time (106.8 min BP vs. 106.4 min placebo, p = 0.94) and length of stay (1.68 days BP vs. 1.48 days placebo, p = 0.40). There were no intraoperative complications and one 30-day readmission for chest pain and dehydration in the placebo group. Utilization of outpatient hydration was equivalent (7.14% BP vs 6.90% placebo, p > 0.99). Anti-emetic usage (53.57% BP and 58.62% placebo, p = 0.70) and self-reported nausea (46.43% BP and 51.72% cohort, p = 0.79) were comparable.
conclusionIntraoperative BP during SG is safe but does not improve peri-operative outcomes or patient-reported PONV when compared to standard ERAS measures. We were limited by reduction in elective bariatric case volume during the pandemic. Future study administering botulinum toxin preoperatively during endoscopy may be more successful.
Indexed as
Identifiers
40879776What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.